Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: An asian perspective

Muhammad Miftahussurur, Yoshio Yamaoka

Research output: Contribution to journalReview articlepeer-review

35 Citations (Scopus)


Asia has the largest population of any continent and the highest incidence of gastric cancer in the world, making it very important in the context of Helicobacter pylori infection. According to current guidelines, standard triple therapy containing a proton pump inhibitor (PPI) and two antibiotics; amoxicillin (AMX) and clarithromycin (CAM) or metronidazole (MNZ), is still the preferred first-line regimen for treatment of H. pylori infection. However, the efficacy of legacy triple regimens has been seriously challenged, and they are gradually becoming ineffective. Moreover, some regions in Asia show patterns of emerging antimicrobial resistance. More effective regimens including the bismuth and non-bismuth quadruple, sequential, and dual-concomitant (hybrid) regimens are now replacing standard triple therapies as empirical first-line treatments on the basis of the understanding of the local prevalence of H. pylori antimicrobial resistance. Selection of PPI metabolized by the non-enzymatic pathway or minimal first pass metabolism and/or increasing dose of PPI are important to increase H. pylori eradication rates. Therefore, local antibiotic resistance surveillance updates, selection of appropriate first-line regimens with non-enzymatic PPI and/or increased doses of PPI, and detailed evaluation of patients' prior antibiotic usage are all essential information to combat H. pylori antibiotic resistance in Asia.

Original languageEnglish
Pages (from-to)6068-6092
Number of pages25
Issue number4
Publication statusPublished - 1 Apr 2015


  • Amoxicillin (AMX)
  • Antibiotic resistance
  • Asia
  • CYP2C19 polymorphisms
  • Clarithromycin (CAM)
  • Helicobacter pylori
  • Metronidazole (MNZ)
  • Proton pump inhibitor (PPI)


Dive into the research topics of 'Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: An asian perspective'. Together they form a unique fingerprint.

Cite this